Biomarin Pharmaceutical Inc (NASDAQ:BMRN)
| 92.88 Delayed Data As of Aug 19 |  -0.08 / -0.09%Today’s Change | 70.73 Today|||52-Week Range 97.76 | +5.13% Year-to-Date |
Latest BMRN News | Press Releases
| Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal Aug 12 / Zacks.com - Paid Partner Content | CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates Aug 09 / Zacks.com - Paid Partner Content |
| Roche (RHHBY) Influenza Drug Gets FDA Nod for Children Aug 12 / Zacks.com - Paid Partner Content | Clearwater Paper and Logitech International have been highlighted as Zacks Bull and Bear of the Day Aug 08 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 92.96 |
| Today’s open | 92.56 |
| Day’s range | 92.22 - 93.28 |
| Volume | 37,423 |
| Average volume (3 months) | 1,144,010 |
| Market cap | $17.6B |
Data as of 4:00pm ET, 08/19/2022
Growth & Valuation
| Earnings growth (last year) | -107.37% |
| Earnings growth (this year) | +303.09% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | +0.20% |
| P/E ratio | 331.7 |
| Price/Sales | 8.75 |
| Price/Book | 4.09 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TECHBio-Techne Corp | -6.56 | -1.81% |
| ---- | ||
| ---- | ||
| NBIXNeurocrine Bioscienc... | +0.34 | +0.32% |
Data as of 4:00pm ET, 08/19/2022
Financials
| Next reporting date | October 26, 2022 |
| EPS forecast (this quarter) | $0.00 |
| Annual revenue (last year) | $1.8B |
| Annual profit (last year) | -$64.1M |
| Net profit margin | -3.47% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Rafael, California |
Forecasts
